Trump Administration Secures Deals with Pharma Giants Eli Lilly and Novo Nordisk to Cut Obesity Drug Costs

---

Full Story

The Trump administration announced pharmaceutical agreements under its Most Favored Nation policy, partnering with Novo Nordisk and Eli Lilly to offer GLP-1 obesity drugs at reduced prices. These deals aim to align U.S. costs with lower international rates, easing burdens on patients nationwide. The policy, rooted in executive actions, targets high-cost medications for chronic conditions.

GLP-1 agonists, like semaglutide and tirzepatide, mimic hormones to regulate blood sugar and appetite, approved by the FDA for diabetes and weight management. The agreements extend discounts to Medicare beneficiaries, covering millions of seniors.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 26% | Right 36% | Center 33% | Unrated 5%

The Context

Historical drug pricing disparities stem from negotiation differences between U.S. and other markets, where governments leverage volume for savings. Trump’s approach revives stalled efforts to import price benchmarks without new legislation.

Manufacturers agree to voluntary caps, avoiding penalties under the policy’s framework established in prior years. Implementation phases roll out over months, monitoring compliance through federal audits.

Proponents hail the moves as victories for affordable healthcare, empowering consumers against monopoly pricing. Skeptics question long-term sustainability, fearing innovation cuts from revenue pressures.

The deals focus on blockbuster drugs generating billions annually, shifting market dynamics toward accessibility. Patient advocacy groups track adherence to promised savings at pharmacies.

Broader views support tying prices to global norms for equity, while industry voices stress R&D funding needs. Balancing cost controls with medical progress remains a core policy tension.

Obesity affects over 40 percent of U.S. adults, per longstanding health data, making these interventions timely. The administration frames the pacts as fulfilling campaign pledges on economic relief.